Benign Prostatic Hyperplasia
Total Payments
$1.1M
Transactions
148
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $1.1M | 148 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.1M | 148 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Effects and Safety of OPK-88004 Doses in Men With Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) | OPKO Pharmaceuticals, LLC | $1.1M | 0 |
Top Doctors Receiving Payments for Benign Prostatic Hyperplasia
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Sacramento, CA | $1.1M | 148 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $1.1M
- Total Doctors 0
- Transactions 148
About Benign Prostatic Hyperplasia
Benign Prostatic Hyperplasia is a drug associated with $1.1M in payments to 0 healthcare providers, recorded across 148 transactions in the CMS Open Payments database. The primary manufacturer is OPKO Pharmaceuticals, LLC.
Payment data is available from 2019 to 2019. In 2019, $1.1M was paid across 148 transactions to 0 doctors.
The most common payment nature for Benign Prostatic Hyperplasia is "Unspecified" ($1.1M, 100.0% of total).
Benign Prostatic Hyperplasia is associated with 1 research study, including "Effects and Safety of OPK-88004 Doses in Men With Signs and Symptoms of Benign Prostatic Hyperplasia (BPH)" ($1.1M).